‘The real key is locating the mutation, which can be an ongoing investigation in collaboration with several other laboratories,’ said Willingham. Cui, Willingham and their colleagues also showed that highly purified organic killer cells, macrophages and neutrophils taken from the cancer-resistant mice killed many different types of tumor cells in laboratory research in check tubes. Besides Cui and Willingham, the team includes Amy M. Hicks, Ph.D., Anne M. Sanders, B.S., Holly M. Weir, M.S., Wei Du, M.D., and Joseph Kim, B.A., from pathology, Greg Riedlinger, B.S., from tumor biology, Martha A. Alexander-Miller, Ph.D., from immunology and microbiology, Mark J.Regrettably, proteins are more complicated than DNA. Complex problems have plagued functional proteomic R&D on every front. Problems connected with functional proteomic technology, such as protein arrays are many also. The development of varied proteomic products and targeted solutions is usually fraught with pitfalls, a lot of which deal with the vast range of chemical and physical properties of different proteins, clarifies Austin. A few of these include the complexity of the protein-interaction map, too little standardization, that makes it tough to evaluate or validate outcomes from different laboratories, and too little protein-specific capture agents such as antibodies.